Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 361

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 361
---
 to the Series B
preferred stockholders at a strike price of $1.50 per share (“New Series B Warrants”), allowing the Series B preferred stockholders to purchase common stock in an amount equal to 33.33% of their current Series B Preferred holdings. The New
Series B Warrants were immediately exercisable and expire five years after issuance. The New Series B Warrants were issued as an incentive for the Series B stockholders to consent to the Series C Offering. The issuance of the New Series B Warrants
was considered an inducement offer under ASC 470, Debt and the Company recorded financing costs based on the grant date fair value of the New Series B Warrants to other expense in the accompanying statement of operations for the year ended
December 31, 2023.

F-26

LB Pharmaceuticals Inc Notes to Financial Statements Warrants outstanding as of December 31, 2024 and 2023 are as follows:

|                            |     | As of December 31, |           |     |      |           |
|                            |     |               2024 |           |     | 2023 |           |
| Class A Warrants           |     |                    |   695,961 |     |      |   695,961 |
| Class B Warrants           |     |                    |   882,948 |     |      |   886,698 |
| Series B-1 Warrants        |     |                    |    71,761 |     |      |    73,199 |
| New Series B Warrants      |     |                    |    98,456 |     |      |   100,373 |
| Placement agent warrants   |     |                    | 1,528,632 |     |      | 1,528,632 |
| Total warrants outstanding |     |                    | 3,277,758 |     |      | 3,284,863 |

See Note 3 Fair Value Measurementsfor warrant activity for the years ended December 31, 2024 and 2023. 9. Net Loss per Share The following table sets forth the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2024 and 2023 (in thousands, except share and per share data):

|                                                                                            |     | Year ended December 31, |       2024 |   |     |   |      2023 |   |
|:-------------------------------------------------------------------------------------------|